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Abstract
Depression affects over 21 million adults in the United States and
continues to rise, making it important to find additional treatments
to alleviate symptoms in adults whose depression is not controlled
on current anti-depressant medication or therapy. Depression has
been shown to be linked to the gut-brain axis, meaning gut health is
connected to our mental health. Probiotics may, therefore, affect the
gut microbiome and ultimately affect cognitive patterns in the brain.
This research analyzes if the use of probiotics improves
psychological wellbeing by managing symptoms of depression
compared to those who do not take probiotics.

Introduction
Depression
§ Tripled amongst Americans during the COVID-19
pandemic
§ Symptoms include persistent low mood, feelings of
worthlessness, change in sleep/eating habits, thoughts of
suicide
§ One-third of patients continue to have depressive symptoms
not controlled with anti-depressants or therapy

Gut-brain axis
§ Bidirectional communication between gut microbiome and
central nervous system via the vagus nerve
§ Gut flora is altered in those with depression
§ Probiotics can potentially restore the gut microbiome,
reducing depressive symptoms

Methods
A literature search was completed using several databases including
PubMed, ClinicalKey, Academic Search Ultimate, and Science
Direct in December 2021. A total of nine randomized clinical
trials were selected based off several inclusion criteria and
critically appraised to analyze the integrity of study design, the
validity of results, and potential translation of the conclusions.

Discussion

Ø Of the nine studies, five reported a decrease in depressive symptoms in
the intervention group.
Ø Of the five studies that measured one or more serum biomarkers to
assess gut inflammation, gut permeability, or tryptophan metabolites,
Kazemi and Tian’s studies showed significant change between the
intervention and control group in terms of inflammation and tryptophan
metabolite changes respectively. Of note, there was evidence that all
biomarkers positively correlated with pain scores in the Chen 2021 study.
Ø Of the five studies that analyzed the fecal microbiome, two showed
significant changes between the intervention and control group in terms
of diversity and presence of certain genera and species of bacteria.
Additionally, in the Chen 2021 study, there were correlations between
certain genera and biomarkers related to gut inflammation.
Table 1. Effects of probiotics reported as measurements of depressive symptoms, blood
biomarkers, and fecal microbiome analysis.
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Depressive Symptoms
Patient
Clinician

Blood
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NA

NS

Findings

• The majority of studies revealed a
significant change in depressive
symptoms between groups
• Varying results could not be attributed
to microbiota strain, baseline severity,
or concomitant antidepressant use

Limitations

• short study duration
• different probiotics used in each study
• small sample size
• antidepressant use not regulated

Future
Research

• longer duration with follow up
• synergistic effects of probiotics plus
antidepressants vs antidepressants
alone
• larger sample sizes
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Key: S = significant, NS = not significant, NA = not applicable

Conclusion
The results of these studies hold promise that probiotic use
sufficiently alters the gut microbiome, exerting change on the
central nervous system to ultimately decrease or completely
eliminate depressive symptoms. They play an especially important
role in patients who are refractory to conventional treatment,
patients who do not seek treatment due to stigma, or patients with
other pathologies related to the gut-brain axis like irritable bowel
syndrome, autism, and obesity. Given the increase of depression
worldwide and the life-altering sequelae associated with severe
disease, the potential of probiotics as therapeutic treatment for
depression should be seriously considered and incorporated into
patient education and multimodal therapy for depression in the
clinical setting.

